TABLE 2.
The roles and mechanisms of FABP5 in various types of cancer.
| Cancer | Biological function | Mechanism | Refs |
|---|---|---|---|
| Gastric cancer | Promotion | FABP-5 gene silencing inhibit cell proliferation, and arrest cell cycle in G0/G1 phase | Zhao et al. (2017) |
| Breast cancer | Suppression | Regulate IFN-β responses in TAMs to enhance the effects of macrophage immune surveillance | Zhang et al. (2014) |
| Breast cancer | Promotion | Activate EGFR and enhance the ability of PPARδ to promote oncogenic properties | Levi et al. (2013) |
| Breast cancer | Promotion | Upregulate the expression of the VEGF gene | Jing et al. (2000) |
| Triple negative breast cancer | Promotion | Stabilize EGFR protein expression by preventing EGFR ubiquitination and degradation leading to metastasis | Powell et al. (2015) |
| Triple negative breast cancer | Promotion | Promote cell survival through the RA-FABP5-PPARβ pathway | Liu et al. (2011) |
| Cervical cancer | Promotion | Reprogram FA metabolism to activate NF-κB signaling, leading to promotion of EMT, lymphangiogenesis and LNM | Zhang et al. (2020) |
| Cervical cancer | Promotion | Promote carcinogenesis and metastasis via up-regulating MMP-2 and MMP-9 | Zhan et al. (2019) |
| Cervical cancer | Promotion | Inhibit MMP-2 and MMP-9 expression in vivo and in vitro | Wang et al. (2016) |
| Clear cell renal cell carcinoma | Promotion | Mediate signaling pathways involved in EMT | Wu et al. (2019) |
| Clear cell renal cell carcinoma | Promotion | Regulate the proliferation via the PI3K/AKT signaling pathway | Lv et al. (2019) |
| Squamous cell carcinoma | Promotion | Rapidly upregulated upon induction of EpCAM as a major target of c-Myc | Uma et al. (2007) |
| Hepatocellular carcinoma | Promotion | Promote angiogenesis and activate the IL6/STAT3/VEGFA pathway | Pan et al. (2018) |
| Hepatocellular carcinoma | Promotion | Induce EMT | Ohata et al. (2017) |
| Intrahepatic cholangiocarcinoma | Promotion | Increase mobilization of fatty acids | Jeong et al. (2012) |
| Prostate cancer | Promotion | Transport excessive amounts of FA into the nucleus to stimulate PPARγ leading to a reduced apoptosis and an increased angiogenesis | Naeem et al. (2019) |
| Prostate cancer | Promotion | FABP5/PPARβ/δ pathway | Morgan et al. (2010) |
| Prostate cancer | Promotion | Hypomethylation of FABP5 promoter leads to the up-regulation of FABP5 transcription by Sp1 and c-Myc | Kawaguchi et al. (2016a) |
| Prostate cancer | Promotion | Interact with PPARγ in a coordinated mechanism to facilitate malignant progression | Forootan et al. (2014) |
| Prostate cancer | Promotion | Activate PPARγ and estrogen-related receptor α | Carbonetti et al. (2019) |
| Prostate cancer | Promotion | Suppression of FABP5 reduces the expression of VEGF and thus inhibit the tumorigenicity | Adamson et al. (2003) |
| Prostate cancer | Promotion | activate PPARγ and upregulate the expression of VEGF. | Bao et al. (2013) |
| Colorectal cancer | Promotion | Promote cell growth and invasion by a PPARβ/δ-independent signaling pathway | Kawaguchi et al. (2016b) |
| Oral squamous cell carcinomas | Promotion | Increase the expression of MMP-9 | Fang et al. (2010) |
| Skin tumor | Suppression | Regulate IFN/p53/SOX2 pathway to suppress skin tumorigenesis | Zhang et al. (2018) |